Lineage Cell Therapeutics LCTX
NYSE LCTX
$0.93 +0.02 (+2.74%)
As of: Oct 2, 2026 · 3:53 PM EDT

Lineage Cell Therapeutics (LCTX) Change in Account Payables (2017)

Updated

Lineage Cell Therapeutics' Change in Account Payables came in at $428,000 for Q3 2017, up 323.8% from the prior quarter.

Analysis

Lineage Cell Therapeutics (LCTX) Change in Account Payables (2017) Analysis & Trends

Over the trailing twelve months to Sep 30, 2017, Lineage Cell Therapeutics reported Change in Account Payables of $760,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Payables (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -70.00 Mn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 18.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -66.70 Mn
10 Lineage Cell Therapeutics 240.26 Mn 38.67 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2017 428,000.00
Jun 30, 2017 101,000.00
Mar 31, 2017 231,000.00
API Access

Lineage Cell Therapeutics Change in Account Payables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=change-in-account-payables&ticker=LCTX&period=max&api_key=YOUR_API_KEY